TAP Activators
TAP Activators constitute a diverse and pivotal group of chemical compounds dedicated to directly enhancing the functional activity of the Transporter associated with Antigen Processing (TAP). This enhancement is achieved through their engagement with specific signaling pathways and biological processes, as demonstrated by the selected compounds in the tabulated form. The paramount significance of TAP Activators lies in their roles in promoting the efficiency of antigen presentation and bolstering immune surveillance mechanisms. Within this category, microbial components like Lipopolysaccharide (LPS) and NOD2 ligands stand out as prominent TAP activators. LPS, through Toll-like receptor 4 (TLR4) signaling, robustly activates TAP, thereby amplifying antigen presentation particularly during bacterial infections. Additionally, synthetic compounds such as Poly(I:C) provide distinctive pathways to activate TAP, offering unique mechanisms to enhance TAP function in the context of immune responses. These activators play pivotal roles in the precise regulation of TAP expression, ensuring the availability of peptides crucial for MHC class I presentation.
Moreover, small molecules like ATP and PMA directly engage with TAP, exerting influence on its functional activity. ATP, by providing essential energy for peptide translocation, ensures the seamless transport of antigens. Simultaneously, PMA activates TAP expression through the PKC signaling pathway, contributing significantly to the efficient presentation of antigens and enhancing immune surveillance capabilities. Furthermore, TAP activators like loxoribine, R848 (Resiquimod), and Imiquimod utilize specific Toll-like receptors, underscoring their essential roles in fostering TAP-mediated antigen presentation during immune responses. In summation, TAP Activators encompass a diverse array of compounds adept at directly enhancing TAP's functional activity through specific and targeted engagement with signaling pathways and biological processes. This comprehensive understanding sheds light on their pivotal roles in augmenting the efficiency of antigen presentation and fortifying immune surveillance, emphasizing their potential as valuable tools in strategies aimed at modulating immune responses.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lipopolysaccharide, E. coli O55:B5 | 93572-42-0 | sc-221855 sc-221855A sc-221855B sc-221855C | 10 mg 25 mg 100 mg 500 mg | $98.00 $171.00 $425.00 $1560.00 | 12 | |
LPS, a component of the outer membrane of Gram-negative bacteria, activates TAP through the Toll-like receptor 4 (TLR4) signaling pathway. Binding of LPS to TLR4 triggers a cascade of events leading to NF-κB activation and subsequent induction of TAP expression. This enhances the antigen presentation process by increasing the availability of peptides for loading onto MHC molecules. | ||||||
ATP | 56-65-5 | sc-507511 | 5 g | $17.00 | ||
ATP serves as an activator of TAP by providing the necessary energy for peptide translocation. ATP binding induces conformational changes in TAP, facilitating the movement of peptides across the membrane. This direct interaction between ATP and TAP enhances the efficiency of antigen processing and presentation by ensuring an adequate energy supply for the translocation of peptides into the endoplasmic reticulum. | ||||||
Polyinosinic acid - polycytidylic acid sodium salt, double-stranded | 42424-50-0 | sc-204854 sc-204854A | 10 mg 100 mg | $139.00 $663.00 | 2 | |
Poly(I:C), a synthetic analog of double-stranded RNA, activates TAP expression through the RIG-I-like receptor (RLR) signaling pathway. The recognition of Poly(I:C) by RLRs triggers downstream signaling events, including IRF3 activation and IFN production. Subsequently, IFN-induced signaling pathways lead to the upregulation of TAP, enhancing the efficiency of antigen processing and presentation during viral infections. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates TAP expression through the PKC (Protein Kinase C) signaling pathway. Binding of PMA to PKC leads to the activation of the ERK/MAPK pathway, subsequently inducing the transcriptional upregulation of TAP genes. This direct activation enhances the peptide transport capacity of TAP, influencing the efficiency of antigen presentation and contributing to immune surveillance against intracellular pathogens and aberrant cells. | ||||||
Loxoribine | 121288-39-9 | sc-203118 sc-203118A | 25 mg 100 mg | $124.00 $390.00 | 1 | |
Loxoribine, a synthetic agonist of TLR7, activates TAP expression through the TLR7/MyD88 signaling pathway. Stimulation of TLR7 by loxoribine initiates a signaling cascade that involves IRF7 and NF-κB activation, resulting in the upregulation of TAP genes. This direct activation enhances the antigen presentation machinery, providing a mechanism for the immune system to recognize and respond to viral infections and other TLR7-activating stimuli. | ||||||
R-848 | 144875-48-9 | sc-203231 sc-203231A sc-203231B sc-203231C | 5 mg 25 mg 100 mg 500 mg | $102.00 $306.00 $510.00 $1559.00 | 12 | |
R848, also known as resiquimod, activates TAP expression through the TLR7/8 signaling pathway. Binding of R848 to TLR7/8 induces a signaling cascade that includes the activation of IRF7 and NF-κB, leading to the transcriptional upregulation of TAP genes. | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $67.00 $284.00 | 6 | |
Imiquimod activates TAP expression through the TLR7/MyD88 signaling pathway. Stimulation of TLR7 by imiquimod initiates a signaling cascade involving IRF7 and NF-κB activation, leading to the transcriptional upregulation of TAP genes. | ||||||